Table 3 In vitro antifungal susceptibilities of 43 clinical C. africana isolates as determined by the Clinical and Laboratory Standards Institute (CLSI) method
From: Multilocus sequence typing analysis of Candida africana from vulvovaginal candidiasis
Candida species | BUC | CLO | FLC | ITC | MIC | TEC | VRC | |
|---|---|---|---|---|---|---|---|---|
C. africana DST 182 (14) | Range GM MIC90 | 0.030–1.00 0.096 0.500 | 0.030–1.00 0.044 0.030 | 0.125–2.00 0.540 2.000 | 0.030–0.03 0.030 0.030 | 0.015–0.50 0.083 0.500 | 0.030–0.50 0.047 0.060 | 0.030–0.25 0.037 0.030 |
C. africana DST 782 (22) | Range GM MIC90 | 0.015–0.25 0.037 0.125 | 0.03–0.125 0.032 0.030 | 0.250–2.00 0.484 1.000 | 0.015–0.03 0.027 0.030 | 0.015–0.25 0.024 0.030 | 0.03–0.125 0.051 0.125 | 0.030–0.06 0.030 0.030 |
C. africana DST 3142 (7) | Range GM MIC90 | 0.030–0.50 0.060 0.250 | 0.030–0.03 0.030 0.030 | 0.250–0.50 0.410 0.500 | 0.030–0.03 0.030 0.030 | 0.015–0.50 0.045 0.500 | 0.03–0.125 0.044 0.060 | 0.03–0.125 0.036 0.030 |
Sub-total (43) | Range GM MIC90 | 0.015–1.00 0.051 0.250 | 0.030–1.00 0.034 0.030 | 0.125–2.00 0.482 1.000 | 0.015–0.03 0.028 0.030 | 0.015–0.50 0.036 0.500 | 0.030–0.50 0.049 0.125 | 0.030–0.25 0.033 0.030 |
C. albicans ATCC90028 (5) | Range GM MIC90 | 0.03–0.125 0.039 0.125 | 0.030–0.06 0.034 0.060 | 0.500–1.00 0.757 1.000 | 0.030–0.06 0.052 0.060 | 0.030–0.50 0.060 0.500 | 0.030 0.030 0.030 | 0.030 0.030 0.030 |